PRORHEM: Robotic Right Hemicolectomy Versus Laparoscopic Right Hemicolectomy

Sponsor
Jeremy Meyer (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06067620
Collaborator
University Hospital, Geneva (Other), Spital Biel, Switzerland (Other), Hôpital Fribourgeois (Other)
70
2
24

Study Details

Study Description

Brief Summary

Robotic right hemicolectomy with intra-corporeal anastomosis may have better short-term recovery outcomes and decreased incidence of incisional hernia when compared to the laparoscopic actual standard of care, for similar safety outcomes.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Robotic right hemicolectomy
  • Procedure: Laparoscopic right hemicolectomy
N/A

Detailed Description

During laparoscopic right hemicolectomy (lapRHC) for cancer or polyp, intra-corporeal anastomosis (ICA) offers better short-term recovery and decreased incidence of incisional hernia (IH) when compared to extra-corporeal anastomosis (ECA). However, because of the technical limitations of laparoscopy, ICA has not gained in wide acceptance and ECA has remained the standard of care. On the contrary, robotics offers improved suturing capacities and facilitates the realization of ICA. Therefore, robotic right hemicolectomy (robRHC) with ICA may have better short-term recovery outcomes and decreased incidence of IH when compared to the laparoscopic actual standard of care. In a randomized controlled trial, we will compare robRHC with ICA with lapRHC with ECA, in terms of recovery of bowel function (time to first passage of faeces). Secondary outcomes will notably include length of stay, incidence of IH, patient-reported esthetical outcomes and safety outcomes (morbidity, mortality, proximal and distal margins, harvested lymph nodes).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Robotic Right Hemicolectomy With Intracorporeal Anastomosis Versus Laparoscopic Right Hemicolectomy With Extracorporeal Anastomosis (PRORHEM): a Randomized Controlled Trial
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
May 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Robotic right hemicolectomy

Robotic right hemicolectomy with intracorporeal anastomosis and extraction through a C-section (fully minimally invasive right hemicolectomy)

Procedure: Robotic right hemicolectomy
Robotic right hemicolectomy with intracorporeal anastomosis and extraction through a C-section, using the Da Vinci Xi.

Active Comparator: Laparoscopic right hemicolectomy

Laparoscopic right hemicolectomy with extracorporeal anastomosis and extraction through midline (standard of care)

Procedure: Laparoscopic right hemicolectomy
Laparoscopic right hemicolectomy with extracorporeal anastomosis and extraction through midline.

Outcome Measures

Primary Outcome Measures

  1. Time to first passage of faeces [From index surgical procedure (skin closure) until time of first passage of faeces, during hospitalisation, on average during the first 7 post-operative days]

    Measured in hours, starting at the skin closure of the index surgery

Secondary Outcome Measures

  1. Duration of surgery [From skin incision to skin closure, during index surgical procedure]

    Measured in minutes

  2. Blood loss [From skin incision to skin closure, during index surgical procedure]

    Measured in ml

  3. Intra-operative transfusion [From skin incision to skin closure, during index surgical procedure]

    Number of patients who received blood and/or blood products transfusion

  4. Intra-operative complication [From skin incision to skin closure, during index surgical procedure]

    Number of patients who experienced a complication during the index surgery

  5. Conversion to open surgery [From skin incision to skin closure, during index surgical procedure]

    Number of patients who had conversion to open surgery; defined as an extraction site longer than 10cm

  6. Length of the extraction site [At post-operative day 30]

    Measured in centimeters

  7. Creation of a stoma [From skin incision to skin closure, during index surgical procedure]

    Number of patients who received a stoma during the index surgery

  8. Hb, WBC and CRP [At post-operative day 1, post-operative day 2, post-operative day 3, post-operative day 4 and post-operative day 5]

    Blood tests

  9. Time to first passage of flatus [From index surgical procedure (skin closure) until time of first passage of flatus, during hospitalisation, on average during the first 7 post-operative days]

    Measured in hours, starting at the skin closure of the index surgery

  10. In-hospital postoperative ileus [During hospitalisation, on average during the first 5 post-operative days]

    Number of patients who experienced a post-operative ileus which required the insertion of a nasogastric tube

  11. Length of stay [From the first day of hospitalisation to the day of discharge, on average during the first 10 post-operative days]

    Measured in days

  12. Post-operative morbidity [From index surgical procedure (skin closure) to post-operative day 30]

    Number of patients who experienced post-operative morbidity, as measured by the Clavien-Dindo scale

  13. Surgical site infection [From index surgical procedure (skin closure) to post-operative day 7 and post-operative day 30]

    Number of patients who experienced surgical site infection

  14. Anastomotic leak [From index surgical procedure (skin closure) to post-operative day 30]

    Number of patients who experienced anastomotic leak, with radiological and/or surgical confirmation

  15. Re-intervention [From index surgical procedure (skin closure) to post-operative day 30]

    Number of patients who required a surgical re-intervention associated with the index surgery

  16. Mortality [From index surgical procedure (skin closure) to post-operative day 30]

    Number of patients who experienced mortality

  17. Proximal margin [Within 10 days from the index surgical procedure]

    Measured in centimeters, on the operative specimen of the index surgery

  18. Distal margin [Within 10 days from the index surgical procedure]

    Measured in centimeters, on the operative specimen of the index surgery

  19. Harvested lymph nodes [Within 10 days from the index surgical procedure]

    Number of harvested lymph nodes, on the operative specimen of the index surgery

  20. Histology of the tumor/polyp [Within 10 days from the index surgical procedure]

    Type of cancer and/or polyp, based on the operative specimen of the index surgery

  21. TNM stage [Within 10 days from the index surgical procedure]

    8th edition of the UICC TNM classification, based on the operative specimen of the index

  22. Bowel function [At post-operative day 30 and post-operative year 1]

    Gastrointestinal Quality of Life Index (GQLI)

  23. Quality of recovery [At post-operative hour 12, post-operative day 1, post-operative day 2, post-operative day 3, post-operative day 4, post-operative day 5 and post-operative day 7]

    Quality of Recovery-15 (QoR-15) score

  24. Aesthetic numeric analogue scale (ANA-scale) [At post-operative day 30 and post-operative year 1]

    Measuring the patient-reported esthetical aspect of the surgical wounds

  25. Incidence of incisional hernia [At post-operative year 1]

    Overall, and at extraction site; measured clinically and by CT

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients requiring elective minimally invasive RHC for polyps not amenable to endoscopic resection or for cTis-T3 Nx M0 cancer of the right colon (including cancer of the appendix, caecum, ascending colon and hepatic flexure).
Exclusion Criteria:
  • Not scheduled for minimally invasive RHC (refuses surgery and/or planned open approach)

  • Emergency surgery

  • Hereditary colorectal cancer

  • Inflammatory bowel disease

  • Synchronous resection of (an)other organ(s)

  • Synchronous surgical procedure (including more extended resection of the lower gastrointestinal tract)

  • cT4

  • cM+

  • History of laparotomy

  • Pregnancy

  • No anastomosis planned

  • Unable to provide informed consent

  • No informed consent

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Jeremy Meyer
  • University Hospital, Geneva
  • Spital Biel, Switzerland
  • Hôpital Fribourgeois

Investigators

  • Study Chair: Christian Toso, MD, PhD, University Hospitals of Geneva

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jeremy Meyer, Principal investigator, University Hospital, Geneva
ClinicalTrials.gov Identifier:
NCT06067620
Other Study ID Numbers:
  • PRORHEM
First Posted:
Oct 5, 2023
Last Update Posted:
Oct 5, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 5, 2023